349 related articles for article (PubMed ID: 33264671)
21. Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates.
Lee NY; Lee CC; Li CW; Li MC; Chen PL; Chang CM; Ko WC
Antimicrob Agents Chemother; 2015 Dec; 59(12):7558-63. PubMed ID: 26416853
[TBL] [Abstract][Full Text] [Related]
22. In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017-2020.
Lee YL; Ko WC; Lee WS; Lu PL; Chen YH; Cheng SH; Lu MC; Lin CY; Wu TS; Yen MY; Wang LS; Liu CP; Shao PL; Shi ZY; Chen YS; Wang FD; Tseng SH; Lin CN; Chen YH; Sheng WH; Lee CM; Tang HJ; Hsueh PR
Int J Antimicrob Agents; 2021 Sep; 58(3):106377. PubMed ID: 34166777
[TBL] [Abstract][Full Text] [Related]
23. Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections in a Chinese Children's Hospital: Predominance of New Delhi Metallo-β-Lactamase-1.
Dong F; Zhang Y; Yao K; Lu J; Guo L; Lyu S; Yang Y; Wang Y; Zheng H; Song W; Liu G
Microb Drug Resist; 2018 Mar; 24(2):154-160. PubMed ID: 28594635
[TBL] [Abstract][Full Text] [Related]
24. Risk factors and mortality for patients with Bloodstream infections of Klebsiella pneumoniae during 2014-2018: Clinical impact of carbapenem resistance in a large tertiary hospital of China.
Chang H; Wei J; Zhou W; Yan X; Cao X; Zuo L; Chen S; Yao K; Huang R; Chen Y; Wu C
J Infect Public Health; 2020 May; 13(5):784-790. PubMed ID: 31843651
[TBL] [Abstract][Full Text] [Related]
25. Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Lo CL; Lee CC; Li CW; Li MC; Hsueh PR; Lee NY; Ko WC
J Microbiol Immunol Infect; 2017 Jun; 50(3):355-361. PubMed ID: 26423244
[TBL] [Abstract][Full Text] [Related]
26. The effect of colistin resistance and other predictors on fatality among patients with bloodstream infections due to Klebsiella pneumoniae in an OXA-48 dominant region.
Menekşe Ş; Çağ Y; Işık ME; Şahin S; Hacıseyitoğlu D; Can F; Ergonul O
Int J Infect Dis; 2019 Sep; 86():208-211. PubMed ID: 31402295
[TBL] [Abstract][Full Text] [Related]
27. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.
Shields RK; Nguyen MH; Chen L; Press EG; Potoski BA; Marini RV; Doi Y; Kreiswirth BN; Clancy CJ
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559250
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network.
Zhang Y; Wang Q; Yin Y; Chen H; Jin L; Gu B; Xie L; Yang C; Ma X; Li H; Li W; Zhang X; Liao K; Man S; Wang S; Wen H; Li B; Guo Z; Tian J; Pei F; Liu L; Zhang L; Zou C; Hu T; Cai J; Yang H; Huang J; Jia X; Huang W; Cao B; Wang H
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203488
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems.
Tan SH; Ng TM; Chew KL; Yong J; Wu JE; Yap MY; Heng ST; Ng WHW; Wan S; Cheok SJH; Tambyah PA; Lye DC
Int J Antimicrob Agents; 2020 Feb; 55(2):105860. PubMed ID: 31841674
[TBL] [Abstract][Full Text] [Related]
31. Bloodstream Infections due to Carbapenem-Resistant
Shen L; Lian C; Zhu B; Yao Y; Yang Q; Zhou J; Zhou H
Microb Drug Resist; 2021 Feb; 27(2):227-233. PubMed ID: 32584202
[TBL] [Abstract][Full Text] [Related]
32. Retrospective Observational Study from a Chinese Network of the Impact of Combination Therapy versus Monotherapy on Mortality from Carbapenem-Resistant
Wang X; Wang Q; Cao B; Sun S; Zhang Y; Gu B; Li B; Liao K; Zhao F; Jin L; Jin C; Yang C; Pei F; Zhang Z; Wang H
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30348660
[TBL] [Abstract][Full Text] [Related]
33. Outcomes associated with empiric cefepime for bloodstream infections caused by ceftriaxone-resistant, cefepime-susceptible Escherichia coli and Klebsiella pneumoniae.
Frescas BE; McCoy CM; Kirby J; Bowden R; Mercuro NJ
Int J Antimicrob Agents; 2023 May; 61(5):106762. PubMed ID: 36804369
[TBL] [Abstract][Full Text] [Related]
34. Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia.
Song W; Moland ES; Hanson ND; Lewis JS; Jorgensen JH; Thomson KS
J Clin Microbiol; 2005 Sep; 43(9):4891-4. PubMed ID: 16145169
[TBL] [Abstract][Full Text] [Related]
35. Risk factors and survival of patients infected with carbapenem-resistant Klebsiella pneumoniae in a KPC endemic setting: a case-control and cohort study.
Cienfuegos-Gallet AV; Ocampo de Los Ríos AM; Sierra Viana P; Ramirez Brinez F; Restrepo Castro C; Roncancio Villamil G; Del Corral Londoño H; Jiménez JN
BMC Infect Dis; 2019 Oct; 19(1):830. PubMed ID: 31590648
[TBL] [Abstract][Full Text] [Related]
36. Outbreak of carbapenem-resistant Klebsiella pneumoniae in Puerto Rico associated with a novel carbapenemase variant.
Gregory CJ; Llata E; Stine N; Gould C; Santiago LM; Vazquez GJ; Robledo IE; Srinivasan A; Goering RV; Tomashek KM
Infect Control Hosp Epidemiol; 2010 May; 31(5):476-84. PubMed ID: 20334553
[TBL] [Abstract][Full Text] [Related]
37. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.
Qureshi ZA; Paterson DL; Potoski BA; Kilayko MC; Sandovsky G; Sordillo E; Polsky B; Adams-Haduch JM; Doi Y
Antimicrob Agents Chemother; 2012 Apr; 56(4):2108-13. PubMed ID: 22252816
[TBL] [Abstract][Full Text] [Related]
38. Healthcare-associated carbapenem-resistant Klebsiella pneumoniae infections are associated with higher mortality compared to carbapenem-susceptible K. pneumoniae infections in the intensive care unit: a retrospective cohort study.
Yao Y; Zha Z; Li L; Tan H; Pi J; You C; Liu B
J Hosp Infect; 2024 Jun; 148():30-38. PubMed ID: 38513959
[TBL] [Abstract][Full Text] [Related]
39. A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting.
Aslan AT; Kırbaş E; Sancak B; Tanrıverdi ES; Otlu B; Gürsoy NC; Yılmaz YA; Tozluyurt A; Liste Ü; Bıçakcıgil A; Hazırolan G; Dağ O; Güven GS; Akova M;
Int J Antimicrob Agents; 2022 Apr; 59(4):106554. PubMed ID: 35176476
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for carbapenem-resistant K. pneumoniae bloodstream infection and predictors of mortality in Chinese paediatric patients.
Zhang Y; Guo LY; Song WQ; Wang Y; Dong F; Liu G
BMC Infect Dis; 2018 May; 18(1):248. PubMed ID: 29855274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]